Oncology Pulmonary Hypertension Patient Engagement Our Science Clinical Trials Compassionate Use & Pre-Approval Access R&D Data Science Janssen Global Trial Finder Research & Development World Without Disease Accelerator Partnerships Precision Medicine and Co-Diagnostics Careers We’re always seeking talented ...
Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Our commitment lies in developing proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy, empowering minimally invasive molecular diagnoses across various stages of disease management...
With precision medicine, we are working on transforming the study of diseases by investing in best-in-class research capabilities in genomics, biotherapeutics, biomarkers, molecular and companion diagnostics, the microbiome, disease interception and prevention, and vaccine platforms. We are accessing early...
OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").
“Patients with mCRPC and BRCA mutations face a more aggressive form of prostate cancer and high unmet needs in terms of treatment options,” said Peter Lebowitz, MD, PhD, Global Therapeutic Area head, Oncology, Janssen Research & Development, LLC. “The data supporting thi...
Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Eva C. Guinan Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA John W. Jackson Department of Epidemiology, Harvard T.H. Chan School of Public...
OncologyGynecologic Oncology Head & Neck Cancers Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive ...
Senior Vice President of OrigiMed for Pharmaceutical Cooperation attended the Janssen - OrigiMed MoU on Strategic Collaboration Signing Ceremony.Najat Khan, PhD, Chief Data Science Officer, Janssen R&D,Zach Boyd, PhD, Head Oncology Diagnostics, Janssen R&D also expressed their sincere wishes and expectat...
ONCOLOGY Progress in the Journey to Transform the Treatment of Bladder Cancer Christopher Cutie, M.D. Vice President Disease Area Stronghold Leader, Bladder Cancer Janssen Research & Development, LLC Apr 30, 2023 LEADERSHIP One Size Fits Not: The "E's" of Accessible Transformational Medicine...